Mirna Therapeutics Inc. (MIRN) Downgraded by Oppenheimer Holdings Inc. to Market Perform
A number of other equities research analysts have also issued reports on the company. Zacks Investment Research raised Mirna Therapeutics from a hold rating to a buy rating and set a $5.00 price target for the company in a research note on Thursday, July 14th. Leerink Swann lowered Mirna Therapeutics from an outperform rating to a market perform rating and decreased their price target for the stock from $10.00 to $4.00 in a research note on Monday, August 15th. Citigroup Inc. lowered Mirna Therapeutics from a buy rating to a neutral rating and decreased their price target for the stock from $7.00 to $4.50 in a research note on Tuesday, August 16th. HC Wainwright began coverage on Mirna Therapeutics in a research note on Monday, September 12th. They set a buy rating and a $6.00 price target for the company. Finally, Cantor Fitzgerald lowered Mirna Therapeutics from a buy rating to a hold rating in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $7.38.
Mirna Therapeutics (NASDAQ:MIRN) traded up 4.00% during trading on Wednesday, hitting $2.08. The stock had a trading volume of 20,466 shares. Mirna Therapeutics has a 12 month low of $1.82 and a 12 month high of $11.01. The stock has a 50 day moving average price of $3.11 and a 200-day moving average price of $4.10. The stock’s market cap is $43.34 million.
Mirna Therapeutics Company Profile
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.